New drug targets Hard-to-Treat colorectal cancer in early trial
NCT ID NCT07463599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, tegavivint, in people with metastatic colorectal cancer that has worsened after at least two prior treatments. The trial aims to find a safe dose and see if the drug shrinks tumors when used alone or with standard therapies. About 126 adults with specific gene mutations will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trials Nurse Navigator
RECRUITINGScottsdale, Arizona, 85258, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••